RANCHO CORDOVA, Calif.,
Oct. 2, 2019 /PRNewswire/ -- Cesca
Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell
processing and autologous cell therapies for regenerative medicine,
and ThermoGenesis, its wholly owned device subsidiary (the
"Company"), announced today it has received the $2 million upfront distribution fee pursuant to
its global distribution agreement, entered into as of August 30, 2019, for the X-Series® product line.
For details of the global distribution agreement, please
refer to the Company's 8-K filed with the U.S. Securities and
Exchange Commission on September 6,
2019.
The X-Series products are major components of the Company's
CAR-TXpress™ platform, a semi-automated, closed cellular
processing platform used for high efficiency cell purification and
cell washing. The X-Series products, when used in combination
with the Company's proprietary buoyancy activated cell sorting
(BACS) technology, can be applied for both research and commercial
manufacturing of a large variety of cell-based therapeutics,
including chimeric antigen receptor-T (CAR-T) cells.
About Cesca Therapeutics and Thermogenesis
Cesca
Therapeutics develops, commercializes and markets a range of
automated technologies for CAR-T and other cell-based therapies.
Its device division, ThermoGenesis develops, commercializes and
markets a full suite of solutions for automated clinical
biobanking, point-of-care applications, and automation for
immuno-oncology. The Company has developed a semi- automated,
functionally closed CAR-TXpress™ platform to streamline the
manufacturing process for the emerging CAR-T immunotherapy market.
For more information about Cesca and ThermoGenesis,
please visit: www.cescatherapeutics.com.
Forward-Looking Statement
The statements contained
herein may include statements of future expectations and other
forward-looking statements that are based on management's current
views and assumptions and involve known and unknown risks and
uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. A more complete description of risks that could cause
actual events to differ from the outcomes predicted by Cesca
Therapeutics' forward-looking statements is set forth under the
caption "Risk Factors" in Cesca Therapeutics' annual report on Form
10-K and other reports it files with the Securities and Exchange
Commission from time to time, and you should consider each of those
factors when evaluating the forward-looking statements.
Company Contact:
Wendy
Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula
Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/cesca-therapeutics-announces-receipt-of-2-million-upfront-distribution-fee-300929424.html
SOURCE Cesca Therapeutics Inc.